Europe Rx Dermatology Topical Drug Delivery Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Publish Reports
  • Europe
  • 350 Pages
  • No of Tables: 18
  • No of Figures: 92
Europe Rx Dermatology Topical Drug Delivery Market By Product Type (Semi-Solid, Liquid, Solid), Application (Skin Infections, Dermatitis, Antiaging, Acne, Hyperpigmentation, Rosacea, Skin Cancer, Psoriasis, Onychomycosis, Others), Category (Branded, Generic), Countries (Germany, France, Italy, U.K., Switzerland, Spain, Netherlands, Russia, Turkey, Belgium, Rest of Europe) – Industry Trends and Forecast to 2026 Topical drugs play an important role in the therapy of dermatologic diseases. Topical dermatology drugs frame a large percentage of products in the drug market. These products are manufactured through specialized manufacturing processes such as precise volume filling, large scale mixing and heating and packaging. Topical drug administration can be done in the body through ophthalmic, rectal, vaginal and skin as topical routes. In dermatology sector, skin plays a major role for the administration of topical drug for the treatment of skin disease in patients. The topical preparations are applied on the skin for surface, local or systemic effects. The topical formulations include therapeutically active ingredients which help in treating the skin diseases in patients. Topical drug delivery is one of the most effective ways of drug delivery as it gives optimum therapeutic outcomes. Gradually, the topical drug delivery system has become increasingly important in the pharmaceutical industry. The pharmacological response, both the desired therapeutic effect and the undesired unfavourable effect of a drug is dependent on the concentration of the drug at the place of action, which in turn depends upon the dosage form and the extent of absorption of the drug at the site of action. In dermatology sector, drug molecule applied on the skin which penetrates the skin primarily through the tortuous and continuous intercellular path. These products are available in different forms such as ointments, creams, lotions, gels and others which have the ability to get absorbed in the body and show the positive response in healing wound respectively. Europe Rx dermatology topical drug delivery market is expected to register a healthy CAGR of 3.8% in the forecast period of 2019-2026.

Segmentation: Europe Rx Dermatology Topical Drug Delivery Market

The Europe Rx dermatology topical drug delivery market is segmented on the basis product type, application, and category.
  • On the basis of product type, the market is segmented into solid, liquid and semi-solid. Solid is sub-segmented into powder and others. Liquid is sub-segmented into solution, emulsion, suspension, lotion and others. Semi-solid is sub-segmented into creams, gel, ointments, paste, others.
    • In December 2016, Pfizer Inc. received approval from U.S. Food and Drug Administration (FDA) for the product called EUCRISATM (crisaborole) ointment 2%. It is a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor. It is used for the treatment of mild to moderate atopic dermatitis (AD). With this launch of the product the company has built a heritage in Inflammation and Immunology sector.
  • On the basis of application, the market is segmented into acne, dermatitis, psoriasis, skin infections, antiaging, skin cancer, hyperpigmentation, onychomycosis, rosacea, others.
    • In March 2017, Galderma Laboratories, L.P., makers of Cetaphil brand launched seven new facial skincare products. With this launch of the products Cetaphil portfolio of the company has increased. The company has now broad range of specialized solutions for the patients with skin concerns, including hydration and others.
  • On the basis of category, the market is segmented into generic and branded.
    • In February 2016, Allergan plc received an approval for its product ACZONE (dapsone) Gel, 7.5% from the U.S. Food and Drug Administration (FDA). This product is a new prescription topical treatment which is useful for the treatment of acne in patients 12 years of age and older. The product helped patient in treating acne easily which ultimately helped in increase in revenue.

Competitive Analysis: Europe Rx Dermatology Topical Drug Delivery Market

Some of the prominent participants operating in this market are Galderma Laboratories, L.P., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., LEO Pharma A/S, GlaxoSmithKline plc., ALLERGAN, Bayer AG, 3M, Bausch Health Companies Inc., The Lubrizol Corporation, Cipla Inc., Kaken Pharmaceutical Co.,Ltd. among others. Recent Developments:
  • In April 2016, Allergan plc acquired Topokine Therapeutics, Inc. with upfront payment of USD 85.8 million and was eligible to receive contingent development and commercialization milestones of up to USD 260.0 million.
  • In February 2019, Kaken Pharmaceutical Co., Ltd. has concluded an exclusive license and distribution agreement for the topical formulation for Onychomycosis in the People’s Republic of China. According to the agreement Kaken Pharmaceutical Co., Ltd., provided exclusive right for the development and commercialization of the Product in PRC and this has led in high revenue generation.
  • In April 2019, The Lubrizol Corporation launched its newest multifunctional, 2- in-1 rheology modifier, Carbopol Style 2.0 polymer. The product has the benefits for the skin care such as smooth glossy appearance, unique formulation textures and others. With this launch the product portfolio of the company has increased which resulted higher revenue generation.
  • In August 2018, Cipla INC. received final approval for Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the U.S. Food and Drug Administration (US FDA). Due to this the company has increased their product portfolio and strong position in market especially in dermatology field.
  • In November 2010, 3M re-launched Cavilon Professional Skin Care line. This product helped in preventing skin damage from moisture, friction and adhesive trauma. The product portfolio of the company has increased in dermatology filed and hence increased healthcare revenue.

Research Methodology: Europe Rx Dermatology Topical Drug Delivery Market

Primary Respondents: Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Pharmaceutical & Biotechnological Researchers, Doctors & Nurses. Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.
SKU-

TABLE OF CONTENTS EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 RESEARCH METHODOLOGY 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7 SECONDARY SOURCES 2.8 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 INCREASING PREVALENCE OF SKIN DISEASE OR CONDITION 3.1.2 RISING AGING POPULATION 3.1.3 GROWTH IN TOPICAL DRUG DELIVERY 3.1.4 INCREASING RESEARCH AND DEVELOPMENT OF NEW DERMATOLOGICAL DRUGS 3.1.5 NEW PRODUCT LAUNCHES

3.2 RESTRAINTS

3.2.1 WEAK REIMBURSEMENT POLICIES 3.2.2 REGULATORY SCENARIO AND PRICING PRESSURE

3.3 OPPORTUNITIES

3.3.1 LOW BIOLOGIC PENETRATION 3.3.2 INCREASED COMPETITION LEADING TO HIGH INVESTMENTS IN R&D TO INNOVATE NEW PRODUCTS 3.3.3 INCREASING MERGERS AND ACQUISITIONS 3.3.4 EMERGING MARKET

3.4 CHALLENGES

3.4.1 SIDE EFFECTS 3.4.2 PRODUCT RECALL 3.4.3 HIGH COMPETITION 3.4.4 PENETRATION INTO THE SMALLER MARKETS

4 EXECUTIVE SUMMARY 5 PREMIUM INSIGHTS 6 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE

6.1 OVERVIEW 6.2 SOLID

6.2.1 POWDER 6.2.2 OTHERS

6.3 SEMI-SOLID

6.3.1 CREAMS 6.3.2 GEL 6.3.3 OINTMENTS 6.3.4 PASTE 6.3.5 OTHERS

6.4 LIQUID

6.4.1 SOLUTION 6.4.2 EMULSION 6.4.3 SUSPENSION 6.4.4 LOTION 6.4.5 OTHERS

7 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION

7.1 OVERVIEW 7.2 SKIN INFECTIONS 7.3 DERMATITIS 7.4 ANTIAGING 7.5 ACNE 7.6 HYPERPIGMENTATION 7.7 ROSACEA 7.8 SKIN CANCER 7.9 PSORIASIS 7.10 ONYCHOMYCOSIS 7.11 OTHERS

8 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY

8.1 OVERVIEW 8.2 BRANDED 8.3 GENERIC

9 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY

9.1 EUROPE

9.1.1 GERMANY 9.1.2 FRANCE 9.1.3 ITALY 9.1.4 U.K. 9.1.5 SWITZERLAND 9.1.6 SPAIN 9.1.7 NETHERLANDS 9.1.8 RUSSIA 9.1.9 TURKEY 9.1.10 BELGIUM 9.1.11 REST OF EUROPE

10 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, COMPANY LANDSCAPE

10.1 COMPANY SHARE ANALYSIS: EUROPE

11 COMPANY PROFILES

11.1 GLAXOSMITHKLINE

11.1.1 COMPANY OVERVIEW 11.1.2 REVENUE ANALYSIS 11.1.3 COMPANY SHARE ANALYSIS 11.1.4 GEOGRAPHICAL PRESENCE 11.1.5 PRODUCT PORTFOLIO 11.1.6 RECENT DEVELOPMENT

11.2 PFIZER INC.

11.2.1 COMPANY OVERVIEW 11.2.2 REVENUE ANALYSIS 11.2.3 COMPANY SHARE ANALYSIS 11.2.4 GEOGRAPHICAL PRESENCE 11.2.5 PRODUCT PORTFOLIO 11.2.6 RECENT DEVELOPMENTS

11.3 GALDERMA LABORATORIES, L.P.

11.3.1 COMPANY OVERVIEW 11.3.2 COMPANY SHARE ANALYSIS 11.3.3 GEOGRAPHICAL PRESENCE 11.3.4 PRODUCT PORTFOLIO 11.3.5 RECENT DEVELOPMENTS

11.4 LEO PHARMA A/S

11.4.1 COMPANY OVERVIEW 11.4.2 REVENUE ANALYSIS 11.4.3 COMPANY SHARE ANALYSIS 11.4.4 GEOGRAPHICAL PRESENCE 11.4.5 PRODUCT PORTFOLIO 11.4.6 RECENT DEVELOPMENTS

11.5 BAUSCH HEALTH COMPANIES INC.

11.5.1 COMPANY OVERVIEW 11.5.2 REVENUE ANALYSIS 11.5.3 COMPANY SHARE ANALYSIS 11.5.4 GEOGRAPHICAL PRESENCE 11.5.5 PRODUCT PORTFOLIO 11.5.6 RECENT DEVELOPMENT

11.6 ALLERGAN

11.6.1 COMPANY OVERVIEW 11.6.2 REVENUE ANALYSIS 11.6.3 COMPANY SHARE ANALYSIS 11.6.4 GEOGRAPHICAL PRESENCE 11.6.5 PRODUCT PORTFOLIO 11.6.6 RECENT DEVELOPMENTS

11.7 3M

11.7.1 COMPANY OVERVIEW 11.7.2 REVENUE ANALYSIS 11.7.3 GEOGRAPHICAL PRESENCE 11.7.4 PRODUCT PORTFOLIO 11.7.5 RECENT DEVELOPMENT

11.8 BAYER AG

11.8.1 COMPANY OVERVIEW 11.8.2 REVENUE ANALYSIS 11.8.3 GEOGRAPHICAL PRESENCE 11.8.4 PRODUCT PORTFOLIO 11.8.5 RECENT DEVELOPMENTS

11.9 CIPLA INC.

11.9.1 COMPANY OVERVIEW 11.9.2 REVENUE ANALYSIS 11.9.3 GEOGRAPHICAL PRESENCE 11.9.4 PRODUCT PORTFOLIO 11.9.5 RECENT DEVELOPMENT

11.10 HISAMITSU PHARMACEUTICAL CO., INC.

11.10.1 COMPANY OVERVIEW 11.10.2 REVENUE ANALYSIS 11.10.3 GEOGRAPHICAL PRESENCE 11.10.4 PRODUCT PORTFOLIO 11.10.5 RECENT DEVELOPMENT

11.11 KAKEN PHARMACEUTICAL CO.,LTD.

11.11.1 COMPANY OVERVIEW 11.11.2 REVENUE ANALYSIS 11.11.3 GEOGRAPHICAL PRESENCE 11.11.4 PRODUCT PORTFOLIO 11.11.5 RECENT DEVELOPMENTS

11.12 THE LUBRIZOL CORPORATION

11.12.1 COMPANY OVERVIEW 11.12.2 GEOGRAPHICAL PRESENCE 11.12.3 PRODUCT PORTFOLIO 11.12.4 RECENT DEVELOPMENT

12 RELATED REPORTS
 

LIST OF TABLES EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

TABLE 1 NUMBER OF FORMULATION COMPONENTS FOR TOPICAL DRUG PRODUCTS MENTIONED BELOW: TABLE 2 NUMBER AND DISTRIBUTION OF PERSONS AGED 60 YEARS OR OVER BY REGION, IN 2017 AND 2050 TABLE 3 LIST OF APPROVED TOPICAL DRUGS TABLE 4 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE , 2017-2026 (USD MILLION) TABLE 5 EUROPE SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 6 EUROPE SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 7 EUROPE SEMI-SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 8 EUROPE SEMI-SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 9 EUROPE LIQUID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 10 EUROPE LIQUID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 11 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION , 2017-2026 (USD MILLION) TABLE 12 EUROPE SKIN INFECTIONS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 13 EUROPE DERMATITIS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 14 EUROPE ANTIAGING IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 15 EUROPE ACNE IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 16 EUROPE HYPERPIGMENTATION IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 17 EUROPE ROSACEA IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 18 EUROPE SKIN CANCER IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 19 EUROPE PSORIASIS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 20 EUROPE ONYCHOMYCOSIS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 21 EUROPE OTHERS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 22 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY , 2017-2026 (USD MILLION) TABLE 23 EUROPE BRANDED IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 24 EUROPE GENERIC IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 25 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017-2026 (USD MILLION) TABLE 26 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 27 EUROPE SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 28 EUROPE LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 29 EUROPE SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 30 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 31 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 32 GERMANY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 33 GERMANY SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 34 GERMANY LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 35 GERMANY SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 36 GERMANY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 37 GERMANY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 38 FRANCE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 39 FRANCE SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 40 FRANCE LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 41 FRANCE SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 42 FRANCE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 43 FRANCE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 44 ITALY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 45 ITALY SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 46 ITALY LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 47 ITALY SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 48 ITALY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 49 ITALY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 50 U.K. RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 51 U.K. SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 52 U.K. LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 53 U.K. SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 54 U.K. RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 55 U.K. RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 56 SWITZERLAND RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 57 SWITZERLAND SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 58 SWITZERLAND LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 59 SWITZERLAND SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 60 SWITZERLAND RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 61 SWITZERLAND RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 62 SPAIN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 63 SPAIN SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 64 SPAIN LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 65 SPAIN SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 66 SPAIN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 67 SPAIN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 68 NETHERLANDS RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 69 NETHERLANDS SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 70 NETHERLANDS LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 71 NETHERLANDS SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 72 NETHERLANDS RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 73 NETHERLANDS RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 74 RUSSIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 75 RUSSIA SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 76 RUSSIA LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 77 RUSSIA SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 78 RUSSIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 79 RUSSIA RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 80 TURKEY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 81 TURKEY SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 82 TURKEY LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 83 TURKEY SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 84 TURKEY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 85 TURKEY RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 86 BELGIUM RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 87 BELGIUM SEMI-SOLID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 88 BELGIUM LIQUID DRUGS IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 89 BELGIUM SOLID IN RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION) TABLE 90 BELGIUM RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION, 2017-2026 (USD MILLION) TABLE 91 BELGIUM RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY, 2017-2026 (USD MILLION) TABLE 92 REST OF EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
 

LIST OF FIGURES EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET

FIGURE 1 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: SEGMENTATION FIGURE 2 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: GEOGRAPHICAL SCOPE FIGURE 3 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: DATA TRIANGULATION FIGURE 4 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: DROC ANALYSIS FIGURE 5 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS FIGURE 6 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: COMPANY RESEARCH ANALYSIS FIGURE 7 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS FIGURE 8 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET FIGURE 9 TOTAL NUMBER OF COMPANIES WITH ACTIVE PIPELINE (2015 TO 2017) FIGURE 10 TOTAL NUMBER OF COMPANIES WITH ACTIVE PIPELINE (2012-2017) FIGURE 11 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: SEGMENTATION FIGURE 12 INCREASING PREVALENCE OF SKIN DISEASES OR CONDITIONS, RISING AGING POPULATION AND GROWTH IN TOPICAL DRUG DELIVERY ARE EXPECTED TO DRIVE THE EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET IN THE FORECAST PERIOD OF 2019 TO 2026 FIGURE 13 SEMI-SOLID IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DERMATOLOGY DRUG DELIVERY MARKET IN 2019 & 2026 FIGURE 14 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: BY PRODUCT TYPE, 2018 FIGURE 15 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: BY APPLICATION, 2018 FIGURE 16 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: BY CATEGORY, 2018 FIGURE 17 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: SNAPSHOT (2018) FIGURE 18 EUROPE RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE 2018 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $3200.00
  • $2500.00
BUY NOW ADD TO CART